Market Cap
$504.9M
CTNM
Contineum Therapeutics, Inc.
$13.12 ▲ +1.00%
Prev close $12.99Market cap$504.9M
ConsensusStrong Buy
12-mo target$22.43 (+70.9%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)17 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CTNM right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$269.9M
Inst. Activity
17 buys / 10 sells
Insider Activity
$0.00 buy / $1.7M sell
Insider Net $
-$1.7M
SEC Reports
4
Price chart 30d -25.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 trading_halt
Halt Resumed: CTNM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-29T19:50:23.000Z | Resumed 2026-09-29T20:00:00.000Z
Sep 8, 2026 Insider
Stengone Carmine N. acquired via exercise 2,500 shares
CEO and President @ $1.01 ($2.5K)
Sep 8, 2026 Insider
Stengone Carmine N. sold 2,500 shares
CEO and President @ $16.46 ($41.1K)
Aug 3, 2026 Insider
Jul 8, 2026 SEC Stengone Carmine N. acquired via exercise 2,500 shares
CEO and President @ $1.01 ($2.5K)
Two C-suite insiders at Contineum Therapeutics (CEO and CSO) sold a combined $132K in open-market sales over a 7-day win
CLUSTER — Impact 2/10
Three top insiders (CEO, CSO, and CMO) at Contineum Therapeutics exercised and sold shares in a coordinated cluster tota
CLUSTER — Impact 3/10
CEO Carmine Stengone and CMO Tim Watkins sold small open-market positions on June 30, 2026, totaling $334K (0.05% of mar
CLUSTER — Impact 2/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,064,345 shares ($33.8M)
Analyst ratings buy % -6.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 28, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Sep 15, 2026 | Jones Trading | MAINTAIN | Buy | 51% |
| Sep 15, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jul 31, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| May 14, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 6 | 5 | 2 | 0 | 0 | 85% |
Price targets
Where 7 covering analysts think CTNM trades over the next 12 months.
$22.43 +70.9% upside Strong Buy
Current$13.12 Low$17.00 Median$22.00 High$28.00 7 analysts
$17.00$28.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 0 bearish, 0 mixed, 4 neutral · avg impact 3.0/10.
NEUTRALCLUSTER2/10
Two C-suite insiders at Contineum Therapeutics (CEO and CSO) sold a combined $132K in open-market sa
Jul 8, 2026
NEUTRALCLUSTER3/10
Three top insiders (CEO, CSO, and CMO) at Contineum Therapeutics exercised and sold shares in a coor
Jul 3, 2026
NEUTRALCLUSTER2/10
CEO Carmine Stengone and CMO Tim Watkins sold small open-market positions on June 30, 2026, totaling
Jul 1, 2026
NEUTRAL8-K5/10
Contineum Therapeutics reported Q4 2025 financial results showing a net loss of $15.2 million and re
Mar 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
trading_halt
Halt Resumed: CTNM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-29T19:50:23.000Z | Resumed 2026-09-29T20:00:00.000Z
Sep 29, 2026
trading_halt
Trading Halt: CTNM — LUDP (Volatility Trading Pause)
Contineum Therapeutics Cl A CS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Aug 3, 2026
earnings_calendar
CTNM Q2 2026 Earnings Scheduled — 2026-08-03
Jun 30, 2026
short_interest_report
Short Interest: CTNM up 29% to 2.1M shares
Settlement 2026-06-30 | Days to cover: 2.97 | ≈5.72% of shares outstanding (est.)
Jun 29, 2026
ftd
FTD: CTNM — 134,282 shares ($1.9M) failed to deliver
Settlement: 20260629, Price: $14.19, FTD Value: $1,905,461.58, CONTINEUM THERAPEUTICS INC CL
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.45 | $-0.51–$-0.40 | -0.9% | +0.0% | 3↑ 3↓ | $0.0B | 7 |
| Next Q | $-0.46 | $-0.55–$-0.33 | 7.0% | -49.1% | 4↑ 2↓ | $0.0B | 7 |
| Current FY | $-1.71 | $-1.85–$-1.52 | 21.1% | -10.1% | 6↑ 1↓ | $0.0B | 7 |
| Next FY | $-1.92 | $-2.55–$-1.43 | -11.8% | -6.6% | 4↑ 2↓ | $0.0B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.454 | — |
| 7d ago | $-0.454 | — |
| 30d ago | $-0.454 | — |
| 60d ago | $-0.455 | +0.001 |
| 90d ago | $-0.429 | -0.026 |
Institutional ownership
Which big funds own CTNM (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $269.9M total value (16,474,110 shares) as of 2026-Q2. Top holders: Jupiter, BlackRock,, FRANKLIN. Net buying activity: 17 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Jupiter Topco LLC | 2,734,836 | $44.8M | 16.6% | — |
| BlackRock, Inc. | 2,064,345 | $33.8M | 12.5% | DOUBLED +208.5% |
| FRANKLIN RESOURCES INC | 1,839,227 | $30.1M | 11.2% | — |
| BALYASNY ASSET MANAGEMENT L.P. | 1,522,793 | $25.0M | 9.2% | ADD +93.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,321,356 | $21.7M | 8.0% | — |
| FMR LLC | 1,040,130 | $17.0M | 6.3% | ADD +27.6% |
| MILLENNIUM MANAGEMENT LLC | 931,709 | $15.3M | 5.7% | TRIM -39.3% |
| GEODE CAPITAL MANAGEMENT, LLC | 693,188 | $11.4M | 4.2% | DOUBLED +145.8% |
| GOLDMAN SACHS GROUP INC | 497,255 | $8.2M | 3.0% | ADD +61.9% |
| STATE STREET CORP | 425,902 | $7.0M | 2.6% | DOUBLED +320.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 669,123 | 2,064,345 | +208.5% | $33.8M |
| FMR LLC | ADD | 814,871 | 1,040,130 | +27.6% | $17.0M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,535,449 | 931,709 | -39.3% | $15.3M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 282,038 | 693,188 | +145.8% | $11.4M |
| GOLDMAN SACHS GROUP INC | ADD | 307,108 | 497,255 | +61.9% | $8.2M |
| STATE STREET CORP | DOUBLED | 101,278 | 425,902 | +320.5% | $7.0M |
| NORTHERN TRUST CORP | DOUBLED | 65,928 | 277,804 | +321.4% | $4.6M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 144,009 | 214,082 | +48.7% | $3.5M |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 59,946 | 178,673 | +198.1% | $2.9M |
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 55,609 | 150,797 | +171.2% | $2.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 50 transactions. Net -$1.7M — $0.00 bought, $1.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Stengone Carmine N. | CEO and President | EXERCISE | 2,500 | $1.01 | $2.5K |
| Sep 8, 2026 | Stengone Carmine N. | CEO and President | SELL | 2,500 | $16.46 | $41.1K |
| Aug 3, 2026 | Stengone Carmine N. | CEO and President | EXERCISE | 2,500 | $1.01 | $2.5K |
| Aug 3, 2026 | Stengone Carmine N. | CEO and President | SELL | 2,500 | $16.01 | $40.0K |
| Jul 9, 2026 | Lorrain Daniel S. | Chief Scientific Officer | EXERCISE | 25 | $1.01 | $25.25 |
| Jul 9, 2026 | Lorrain Daniel S. | Chief Scientific Officer | SELL | 25 | $16.00 | $400.00 |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President | EXERCISE | 2,500 | $1.01 | $2.5K |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President | SELL | 2,500 | $16.00 | $40.0K |
| Jul 8, 2026 | Lorrain Daniel S. | Chief Scientific Officer | EXERCISE | 1,015 | $1.01 | $1.0K |
| Jul 8, 2026 | Lorrain Daniel S. | Chief Scientific Officer | SELL | 1,015 | $16.00 | $16.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CTNM.
Shares short
2,443,708
Settlement Sep 15, 2026
Change vs prior
+4.4%
Semi-monthly cycle
Days to cover
6.9
At avg daily volume
Of shares outstanding
≈6.5%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 29, 2026 | LUDP | Volatility Pause | Resumed |
All CTNM filing & press-release reports (4)
- CLUSTER reportJul 8, 2026
- CLUSTER reportJul 3, 2026
- CLUSTER reportJul 1, 2026
- 8-K reportMar 5, 2026